Clinical Trial

A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
A Multicenter, Observational Study on the Real-World Effectiveness and Safety of inavolisib Combined with Endocrine Therapy With or Without a CDK4/6 Inhibitor in Patients with HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer.
Trial Details
NCT Number NCT07543250
Lead Sponsor xuliang
Conditions Breast Cancer
Enrollment 100 participants
Start Date 2026-05-16
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-21